Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism
Fig 3
Double-reciprocal plot showing competitive inhibition of DPP-4 by trelagliptin.
Initial rate (first 40 seconds only) was measured as described under Materials and Methods using a range of GP-pNA substrate concentrations bracketing the apparent Km value at several fixed trelagliptin concentrations.